Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Interest Expenses (2016 - 2026)

Cumberland Pharmaceuticals' Interest Expenses history spans 16 years, with the latest figure at $112942.0 for Q4 2025.

  • On a quarterly basis, Interest Expenses fell 49.41% to $112942.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $495990.0, a 18.09% decrease, with the full-year FY2025 number at $495990.0, down 18.09% from a year prior.
  • Interest Expenses hit $112942.0 in Q4 2025 for Cumberland Pharmaceuticals, up from $109699.0 in the prior quarter.
  • Over the last five years, Interest Expenses for CPIX hit a ceiling of $223261.0 in Q4 2024 and a floor of $20021.0 in Q3 2021.
  • Historically, Interest Expenses has averaged $122669.2 across 5 years, with a median of $122961.0 in 2022.
  • Biggest five-year swings in Interest Expenses: crashed 78.35% in 2021 and later soared 645.92% in 2022.
  • Tracing CPIX's Interest Expenses over 5 years: stood at $27734.0 in 2021, then surged by 547.06% to $179456.0 in 2022, then decreased by 0.37% to $178792.0 in 2023, then increased by 24.87% to $223261.0 in 2024, then tumbled by 49.41% to $112942.0 in 2025.
  • Business Quant data shows Interest Expenses for CPIX at $112942.0 in Q4 2025, $109699.0 in Q3 2025, and $109547.0 in Q2 2025.